Should You Buy Ladbrokes PLC Instead Of AstraZeneca plc & International Consolidated Airlins Grp SA?

Could Ladbrokes PLC (LON: LAD) outperform the likes of AstraZeneca plc (LON: AZN) and International Consolidated Airlins Grp SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in betting firm Ladbrokes (LSE: LAD) have fallen by just 0.5% today despite the company reporting a hugely disappointing set of first half results. In fact, it has swung from a pretax profit in the first half of 2014 to a pretax loss in the first half of 2015, with shop closures and impairments contributing to a £51m pretax loss in the six months to June 30.

Clearly, this is hugely disappointing for the company’s investors and, while Ladbrokes has been touted as a strong dividend play owing to its relatively high yield, dividends have understandably been slashed. The company will now pay out 1p per share in its interim dividend, which is well down on the 4.3p per share that was paid in the first six months of last year.

Of course, the gaming industry is enduring a highly challenging period, with competition being very high and margins being squeezed. As such, sector consolidation is inevitable and Ladbrokes’ planned merger with Coral seems to make a lot of sense due to potential synergies and efficiencies that can be made. However, the road to recovery will be a challenging one and, while shares in Ladbrokes have already fallen by 16% in the last year, there could be further falls to come. As such, now does not appear to be the right time to buy a slice of the company.

However, there are a number of stunning investment opportunities within the FTSE 350. Notably, pharmaceutical company AstraZeneca (LSE: AZN) appears to offer a very bright future of growth and, while it has endured a difficult period in recent years as a result of the loss of patents, it is expected to begin delivering growth in the next few years.

Undoubtedly, AstraZeneca is not yet the finished product, with further acquisitions required in order to improve its pipeline. However, the strategy being adopted by the business is very sound and has seen AstraZeneca focus on treatments for health issues such as diabetes, which are expected to become major global challenges in the long run. Therefore, it is positioning itself for excellent long term growth and, even though a bid approach is less likely following the closing of a US tax loophole, its yield of 4.1% and price to earnings (P/E) ratio of 15.9 continue to indicate that it is a very strong buy.

Similarly, IAG (LSE: IAG), owner of British Airways, has also struggled to post strong financial numbers in recent years. For example, it made a loss in 2012 but, with an improving global economy and lower oil price positively impacting sales and costs respectively, its profitability is on the rise. For example, IAG is forecast to increase its bottom line by 75% this year and by a further 20% next year. This could improve investor sentiment moving forward and, even though IAG has posted a share price rise of 67% in the last year, its price to earnings growth (PEG) ratio of just 0.2 indicates that there could be further growth to come.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »